Status:
COMPLETED
The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Lead Sponsor:
University of Aarhus
Conditions:
Change in Bone Mineral Density
Change in Bone Marrow Fat Content
Eligibility:
FEMALE
60-75 years
Phase:
PHASE2
Brief Summary
Osteoporosis is a generalised bone disease leading to an increased risk of fractures. The disease is caused partly by environmental and partly by genetic factors. It is well known that the fat content...
Eligibility Criteria
Inclusion
- Postmenopausal women age 60-75 with no rosiglitazone allergy
Exclusion
- Osteoporosis
- Diabetes
- Hyperthyroidism, untreated hypothyroidism, hyperparathyroidism
- Treatment with bone active drugs
- Low impact fracture
- Heart disease
- Kidney failure
- Liver failure
- Anaemia
- Ineligibility for MRI-scan
- Cancer within last 5 years
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00609362
Start Date
January 1 2008
End Date
November 1 2009
Last Update
April 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8000 C